Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen
Top
Quality of Life Research
Gepubliceerd in:

06-04-2024 | Review

Health-related quality of life in Parkinson’s disease: systematic review and meta-analysis of EuroQol (EQ-5D) utility scores

Auteurs: Raghu Bhanupriya, Madhumitha Haridoss, Goda Suchitra Lakshmi, Bhavani Shankara Bagepally

Gepubliceerd in: Quality of Life Research | Uitgave 7/2024

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Introduction

Evaluating the Health-related quality of life (HRQoL) of individuals with Parkinson’s disease (PD) holds significant importance in clinical and research settings. The EQ-5D is a widely recognized tool for comprehensive measurement of HRQoL using utility values. This study aims to systematically review and synthesize EQ-5D utility values from existing literature on patients with PD and their caregivers.

Methods

We conducted a systematic search for studies that provided EQ-5D utility scores for patients with PD, using PubMed-Medline, Scopus, and Embase and selected the studies. The selected studies underwent systematic review, including an assessment of their quality. We performed a meta-analysis using a random-effect model and conducted a meta-regression analysis to investigate sources of heterogeneity among the studies.

Results

The search result of 13,417 articles that were reviewed, 130 studies with 33,914 participants were selected for systematic review, and 79 studies were included for meta-analysis. The pooled EQ-5D utility values and visual analog score (VAS) among PD were 62.72% (60.53–64.93, I2 = 99.56%) and 0.60 (0.55–0.65, I2 = 99.81%), respectively. The pooled scores for caregivers’ EQ-VAS and EQ-5D utility were 70.10% (63.99–76.20, I2 = 98.25%) and 0.71 (0.61–0.81, I2 = 94.88%), respectively. Disease duration (P < 0.05) showed a negative correlation with EQ-5D utility values on meta-regression.

Conclusion

The pooled utility values of PD and their caregivers help to understand their HRQoL and aid in conducting health economics research. The negative association between disease duration and utility values highlights the evolving nature of HRQoL challenges, suggesting the need for appropriate long-term disease management.
vorige artikel Can prediction models for hospital readmission be improved by incorporating patient-reported outcome measures? A systematic review and narrative synthesis
volgende artikel Differences and common ground in the frameworks of health-related quality of life in traditional Chinese medicine and modern medicine: a systematic review
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
DeMaagd, G., & Philip, A. (2015). Parkinson’s disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. Pharmacy and Therapeutics, 40(8), 504–532.PubMedPubMedCentral
2.
Liaison, C. A. P., (2015) Parkinson’s disease: Challenges, progress, and promise, NINDS. September 30, 2015
3.
Antonina Kouli, K. M. T., & Wei-Li K., (2018) Parkinson’s disease: Pathogenesis and clinical aspects. NIH NLM
4.
5.
Lubomski, M., Davis, R. L., & Sue, C. M. (2021). Health-related quality of life for Parkinson’s disease patients and their caregivers. Journal of Movement Disorders, 14(1), 42–52.PubMedPubMedCentralCrossRef
6.
Lee, J., et al. (2019). Quality of life of caregivers of individuals with Parkinson’s disease. Rehabilitation Nursing, 44(6), 338–348.PubMedCrossRef
7.
Bhimani, R. (2014). Understanding the burden on caregivers of people with Parkinson’s: A scoping review of the literature. Rehabilitation Research and Practice, 2014, 718527.PubMedPubMedCentralCrossRef
8.
Thieken, F., & van Munster, M. (2021). Deriving implications for care delivery in Parkinson’s disease by co-diagnosing caregivers as invisible patients. Brain Sciences, 11(12), 1629.PubMedPubMedCentralCrossRef
9.
10.
S. Heath, R., MS, & E. Lanier, RN, MS. (2023). Parkinson’s disease and caregiving
11.
Hoffmann & Rodrigues, S. E. A. (2016). The challenging roles of informal carers
12.
Norlin, J. M., Kellerborg, K., Persson, U., Åström, D. O., Hagell, P., Martinez-Martin, P., & Odin, P. (2023). Clinical impression of severity index for Parkinson’s disease and its association to health-related quality of life. Movement Disorders Clinical Practice, 10(3), 392–398.PubMedPubMedCentralCrossRef
13.
Afentou, N., et al. (2019). Economic evaluation of interventions in Parkinson’s disease: A systematic literature review. Movement Disorders Clinical Practice, 6(4), 282–290.PubMedPubMedCentralCrossRef
14.
Jørgensen, J., Servos, S., & Kefalas, P. (2018). The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease. J Mark Access Health Policy, 6(1), 1500419.PubMedPubMedCentralCrossRef
15.
16.
17.
Wu, H., et al. (2021). Cost-utility analysis of palliative care in patients with advanced cancer: A retrospective study. BMC Palliative Care, 20(1), 126.PubMedPubMedCentralCrossRef
18.
Liberati, A., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Journal of Clinical Epidemiology, 62(10), e1-34.PubMedCrossRef
19.
Balestroni, G., & Bertolotti, G. (2012). EuroQol-5D (EQ-5D): An instrument for measuring quality of life. Monaldi Archives for Chest Disease, 78(3), 155–159.PubMed
20.
Pattanaphesaj, J., & Thavorncharoensap, M. (2015). Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients. Health and Quality of Life Outcomes, 13, 14.PubMedPubMedCentralCrossRef
21.
Claire, M. N., et al. (2016). The EQ-5D-5L health status questionnaire in COPD: Validity, responsiveness and minimum important difference. Thorax, 71(6), 493.CrossRef
22.
Janssen, M. F., Bonsel, G. J., & Luo, N. (2018). Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. PharmacoEconomics, 36(6), 675–697.PubMedPubMedCentralCrossRef
23.
Moradi, N., et al. (2022). Psychometric properties of the EQ-5D-5L compared with EQ-5D-3L in cancer patients in Iran. Frontiers in Oncology, 12, 1052155.PubMedPubMedCentralCrossRef
24.
McCaffrey, N., et al. (2016). Health-related quality of life measured using the EQ-5D–5L: South Australian population norms. Health and Quality of Life Outcomes, 14(1), 133.PubMedPubMedCentralCrossRef
25.
Antonini, A., et al. (2015). Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism & Related Disorders, 21, 231–235.CrossRef
26.
A’Campo, L. E. I., et al. (2010). The benefits of a standardized patient education program for patients with Parkinson’s disease and their caregivers. Parkinsonism and Related Disorders, 16(2), 89–95.PubMedCrossRef
27.
Carter, B., et al. (2021). A single patient reported outcome measure for acquired brain injury, multiple sclerosis & Parkinson’s disease. PloS ONE, 16(6), e0251484.PubMedPubMedCentralCrossRef
28.
Balzer-Geldsetzer, M., et al. (2018). Quality of life in a German cohort of Parkinson’s patients assessed with three different measures. Journal of Neurology, 265(11), 2713–2722.PubMedCrossRef
29.
30.
Bock, M. A., et al. (2022). Association of Motor and nonmotor symptoms with health-related quality of life in a large online cohort of people with Parkinson disease. Neurology, 98(22), E2194–E2203.PubMedPubMedCentralCrossRef
31.
Brettschneider, C., et al. (2013). Relative impact of multimorbid chronic conditions on health-related quality of life–results from the MultiCare Cohort Study. PloS ONE, 8(6), e66742.PubMedPubMedCentralCrossRef
32.
Cano-de-la-Cuerda, R., et al. (2011). Axial rigidity and quality of life in patients with Parkinson’s disease: A preliminary study. Quality of Life Research, 20(6), 817–823.PubMedCrossRef
33.
34.
Kelly, D. H., et al. (2012). Health-related quality of life and strain in caregivers of Australians with Parkinson’s disease: An observational study. BMC Neurology, 12, 57.PubMedPubMedCentralCrossRef
35.
Cubo, E., et al. (2014). Comparison of the clinical profile of Parkinson’s disease between Spanish and Cameroonian cohorts. Journal of the Neurological Sciences, 336, 122–126.PubMedCrossRef
36.
Torny, F., et al. (2018). Factors associated with spousal burden in Parkinson’s disease. Revue Neurologique, 174(10), 711–715.PubMedCrossRef
37.
Genc, G., et al. (2016). Socioeconomic status may impact functional outcome of deep brain stimulation surgery in Parkinson’s disease. Neuromodulation: Journal of the International Neuromodulation Society, 19(1), 25–30.PubMedCrossRef
38.
39.
Goel, A., Narayan, S. K., & Sugumaran, R. (2022). A telephonic survey of health-related quality of life of outpatient department dropout Parkinson’s disease patients during the COVID-19 pandemic. Acta Neurologica Belgica, 122(2), 519–523.PubMedPubMedCentralCrossRef
40.
41.
Shin, H., et al. (2012). Caregiver burden in Parkinson disease with dementia compared to Alzheimer disease in Korea. Journal of Geriatric Psychiatry and Neurology, 25(4), 222–226.PubMedCrossRef
42.
Horváth, K., et al. (2014). Test-retest validity of Parkinson’s disease sleep scale 2nd version (PDSS-2). Journal of Parkinson’s Disease, 4(4), 687–691.PubMedCrossRef
43.
Sturkenboom, I. H., et al. (2015). Economic evaluation of occupational therapy in Parkinson’s disease: A randomized controlled trial. Movement Disorders: Official Journal of the Movement Disorder Society, 30(8), 1059–67.PubMedCrossRef
44.
Marinus, J., et al. (2003). A short psychosocial questionnaire for patients with Parkinson’s disease: The SCOPA-PS. Journal of Clinical Epidemiology, 56(1), 61–7.PubMedCrossRef
45.
Tollár, J., et al. (2019). Two-year agility maintenance training slows the progression of Parkinsonian symptoms. Medicine and Science in Sports and Exercise, 51(2), 237–245.PubMedCrossRef
46.
Tan, L. C. S., et al. (2004). Validity and reliability of the PDQ-39 and the PDQ-8 in English-speaking Parkinson’s disease patients in Singapore. Parkinsonism & Related Disorders, 10(8), 493–9.CrossRef
47.
Leavy, B., et al. (2020). Outcome evaluation of highly challenging balance training for people with Parkinson disease: A multicenter effectiveness-implementation study. Journal of Neurologic Physical Therapy, 44(1), 15–22.PubMedCrossRef
48.
Blandy, L. M., et al. (2015). Therapeutic argentine tango dancing for people with mild Parkinson’s disease: A feasibility study. Frontiers in Neurology, 6, 122.PubMedPubMedCentralCrossRef
49.
Pillas, M., et al. (2016). Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL carers). Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 25(1), 81–8.PubMedCrossRef
50.
Marinus, J., et al. (2008). Evaluation of the Dutch version of the Parkinson’s disease questionnaire 39. Parkinsonism and Related Disorders, 14(1), 24–27.PubMedCrossRef
51.
Bianchi, M. L. E., et al. (2019). Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 40(2), 275–279.PubMedCrossRef
52.
Müller, T., & Woitalla, D. (2010). Quality of life, caregiver burden and insurance in patients with Parkinson’s disease in Germany. European Journal of Neurology, 17(11), 1365–1369.PubMedCrossRef
53.
54.
Simuni, T., et al. (2013). Rankin scale as a potential measure of global disability in early Parkinson’s disease. Journal of Clinical Neuroscience, 20, 1200–1203.PubMedPubMedCentralCrossRef
55.
56.
Zhang, Z., et al. (2018). Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: A randomized, double-blind study in China. Translational Neurodegeneration, 7, 1–11.
57.
Winter, Y., et al. (2010). Social and clinical determinants of quality of life in Parkinson’s disease in a Russian cohort study. Parkinsonism and Related Disorders, 16(4), 243–248.PubMedCrossRef
58.
Tollar, J., Nagy, F., & Hortobágyi, T. (2019). Vastly different exercise programs similarly improve Parkinsonian symptoms: A randomized clinical trial. Gerontology, 65(2), 120–127.PubMedCrossRef
59.
Gray, R., et al. (2022). Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists among patients with Parkinson disease uncontrolled by levodopa therapy: The PD MED randomized clinical trial. JAMA Neurology, 79(2), 131–140.PubMedCrossRef
60.
Acampo, L. E. I., et al. (2010). Caregiver education in Parkinson’s disease: Formative evaluation of a standardized program in seven European countries. Quality of Life Research: An International Journal of Quality Of life Aspects of Treatment, Care and Rehabilitation, 19(1), 55–64.PubMedCrossRef
61.
Luo, N., et al. (2005). Validity and reliability of the Chinese (Singapore) version of the Parkinson’s disease questionnaire (PDQ-39). Quality of Life Research, 14(1), 273–279.PubMedCrossRef
62.
Svetel, M., et al. (2019). Clinical course of patients with pantothenate kinase-associated neurodegeneration (PKAN) before and after DBS surgery. Journal of Neurology, 266(12), 2962–2969.PubMedCrossRef
63.
Matias, C. M., et al. (2018). Deep brain stimulation outcomes in patients implanted under general anesthesia with frame-based stereotaxy and intraoperative MRI. Journal of Neurosurgery, 129(6), 1572–1578.PubMedCrossRef
64.
Minar, M., et al. (2022). Restless legs syndrome in Parkinson’s disease: Relationship with quality of life and medication. Bratislava Medical Journal, 123(1), 55–60.PubMedCrossRef
65.
Müller, T., Muhlack, S., & Woitalla, D. (2011). Pain perception, pain drug therapy and health status in patients with Parkinson’s disease. Neuroepidemiology, 37(3), 183–187.PubMedCrossRef
66.
Ghislandi, S., et al. (2002). Is EQ-5D a valid measure of HRQoL in patients with movement disorders? A comparison with SF-36 and FIM questionnaires. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care, 3(2), 125–130.PubMedCrossRef
67.
Kalampokini, S., et al. (2022). Caregiver burden in late-stage Parkinsonism and its associations. Journal of Geriatric Psychiatry and Neurology, 35(1), 110–120.PubMedCrossRef
68.
Schrag, A., et al. (2007). Testing the validity of the PDQ-39 in patients with MSA. Parkinsonism & Related Disorders, 13(3), 152–156.CrossRef
69.
Vibha, D., et al. (2011). RBD in Parkinson’s disease: A clinical case control study from North India. Clinical Neurology and Neurosurgery, 113(6), 472–476.PubMedCrossRef
70.
Visser, M., et al. (2008). A comprehensive model of health-related quality of life in Parkinson’s disease. Journal of Neurology, 255(10), 1580–1587.PubMedCrossRef
71.
Cano-de-la-Cuerda, R., et al. (2014). Isokinetic dynamometry as a technologic assessment tool for trunk rigidity in Parkinson’s disease patients. NeuroRehabilitation, 35(3), 493–501.PubMedCrossRef
72.
Alvarado-Bolaños, A., et al. (2015). Convergent validation of EQ-5D-5L in patients with Parkinson’s disease. Journal of the Neurological Sciences, 358(1), 53–57.PubMedCrossRef
73.
Siderowf, A., Ravina, B., & Glick, H. A. (2002). Preference-based quality-of-life in patients with Parkinson’s disease. Neurology, 59(1), 103–108.PubMedCrossRef
74.
Abboud, H., et al. (2015). Impact of mild cognitive impairment on outcome following deep brain stimulation surgery for Parkinson’s disease. Parkinsonism & Related Disorders, 21(3), 249–253.CrossRef
75.
Wojtowicz, A. L., et al. (2019). Is Parkinson’s disease associated with increased mortality, poorer outcomes scores, and revision risk after THA? Findings from the Swedish hip arthroplasty register. Clinical Orthopaedics and Related Research, 477(6), 1347–1355.PubMedPubMedCentralCrossRef
76.
Alonso-Morán, E., et al. (2015). Health-related quality of life and multimorbidity in community-dwelling telecare-assisted elders in the Basque Country. European Journal of Internal Medicine, 26(3), 169–175.PubMedCrossRef
77.
Bega, D., et al. (2015). Impact of depression on progression of impairment and disability in early Parkinson’s disease. Movement Disorders Clinical Practice, 2(4), 371–378.PubMedPubMedCentralCrossRef
78.
Benito-León, J., et al. (2012). Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: The ANIMO study. Movement Disorders, 27(2), 211–218.PubMedCrossRef
79.
Beretzky, Z., & Péntek, M. (2017). Characteristics and determinants of informal care in chronic diseases in Hungary: A comparative analysis. Orvosi Hetilap, 158(52), 2068–2078.PubMedCrossRef
80.
Bugalho, P., et al. (2021). Progression in Parkinson’s disease: variation in motor and non-motor symptoms severity and predictors of decline in cognition, motor function, disability, and health-related quality of life as assessed by two different methods. Movement Disorders Clinical Practice, 8(6), 885–895.PubMedPubMedCentralCrossRef
81.
Chen, G., et al. (2018). Converting Parkinson-specific scores into health state utilities to assess cost-utility analysis. Patient, 11(6), 665–675.PubMedCrossRef
82.
Cheung, Y. B., et al. (2008). Mapping the eight-item Parkinson’s disease questionnaire (PDQ-8) to the EQ-5D utility index. Quality of Life Research, 17(9), 1173–1181.PubMedCrossRef
83.
Clarke, C. E., et al. (2016). Physiotherapy and occupational therapy vs no therapy in mild to moderate Parkinson disease. JAMA Neurology, 73(3), 291–299.PubMedCrossRef
84.
Cubí-Mollá, P., De Vries, J., & Devlin, N. (2014). A study of the relationship between health and subjective well-being in Parkinson’s disease patients. Value Health, 17(4), 372–379.PubMedCrossRef
85.
Daley, D. J., et al. (2014). Adherence therapy improves medication adherence and quality of life in people with Parkinson’s disease: A randomised controlled trial. International Journal of Clinical Practice, 68(8), 963–971.PubMedCrossRef
86.
Dzingina, M. D., McCrone, P., & Higginson, I. J. (2017). Does the EQ-5D capture the concerns measured by the Palliative care Outcome Scale? Mapping the Palliative care Outcome Scale onto the EQ-5D using statistical methods. Palliative Medicine, 31(8), 716–725.PubMedCrossRef
87.
Emma, M., et al. (2016). Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson’s: Economic evaluation alongside the PD SURG trial. Movement Disorders, 31, 1173–1182.CrossRef
88.
Ebersbach, G., et al. (2010). Tolcapone improves sleep in patients with advanced Parkinson’s disease (PD). Archives of Gerontology and Geriatrics, 51(3), e125–e128.PubMedCrossRef
89.
90.
91.
Carod-Artal, F. J., Mesquita, H. M., et al. (2013). Burden and health-related quality of life among caregivers of Brazilian Parkinson’s disease patients. Parkinsonism & Related Disorders, 19(11), 943–948.CrossRef
92.
Carod-Artal, F. J., & Martinez-Martin, P. (2013). Independent validation of the non motor symptoms scale for Parkinson’s disease in Brazilian patients. Parkinsonism & Related Disorders, 19(1), 115–119.CrossRef
93.
Fletcher, E., Goodwin, V. A., Richards, S. H., Campbell, J. L., & Taylor, R. S. (2012). An exercise intervention to prevent falls in Parkinson’s: an economic evaluation. BMC Health Services Research, 12, 1–9.CrossRef
94.
Deli, G., et al. (2015). Deep brain stimulation can preserve working status in Parkinson’s disease. Parkinson’s Disease, 2015, 936865.PubMedPubMedCentral
95.
Nielsen, G., et al. (2017). Randomised feasibility study of physiotherapy for patients with functional motor symptoms. Journal of Neurology, Neurosurgery, and Psychiatry, 88(6), 484–490.PubMedCrossRef
96.
García-Gordillo, M., et al. (2014). Validation and comparison of 15-D and EQ-5D-5L instruments in a Spanish Parkinson’s disease population sample. Quality of Life Research, 23(4), 1315–1326.PubMedCrossRef
97.
Hechtner, M. C., et al. (2014). Quality of life in Parkinson’s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism & Related Disorders, 20(9), 969–974.CrossRef
98.
Hurwitz, B., et al. (2005). Scientific evaluation of community-based Parkinson’s disease nurse specialists on patient outcomes and health care costs. Journal of Evaluation in Clinical Practice, 11(2), 97–110.PubMedCrossRef
99.
Jarman, B., et al. (2002). Effects of community based nurses specialising in Parkinson’s disease on health outcome and costs: Randomised controlled trial. British Medical Journal, 324(7345), 1072–1075.PubMedPubMedCentralCrossRef
100.
Järvelä, J. T., & Kaasinen, V. (2016). Pharmacotherapy and generic health-related quality of life in Parkinson’s disease. Acta Neurologica Scandinavica, 134(3), 205–209.PubMedCrossRef
101.
Johansson, D., et al. (2018). Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry. CNS Neuroscience and Therapeutics, 24(5), 439–447.PubMedPubMedCentralCrossRef
102.
Klotsche, J., et al. (2011). Trajectory classes of decline in health-related quality of life in Parkinson’s disease: A pilot study. Value in Health, 14(2), 329–338.PubMedCrossRef
103.
104.
Larisch, A., et al. (2011). Does the clinical practice guideline on Parkinson’s disease change health outcomes? A cluster randomized controlled trial. Journal of Neurology, 258(5), 826–834.PubMedCrossRef
105.
Luo, N., et al. (2009). Is EQ-5D a valid quality of life instrument in patients with Parkinson’s disease? A study in Singapore. Annals of the Academy of Medicine, Singapore, 38(6), 521–528.PubMedCrossRef
106.
Norlin, J., et al. (2022). Quality of life and resource utilization-Swedish data from the care of late-stage Parkinsonism (CLaSP) study. Acta Neurologica Scandinavica, 145(6), 743–752.CrossRef
107.
Martínez-Martín, P., et al. (2005). Quality of life of caregivers in Parkinson’s disease. Quality of Life Research, 14(2), 463–472.PubMedCrossRef
108.
Martínez-Martín, P., et al. (2007). Caregiver burden in Parkinson’s disease. Movement Disorders, 22(7), 924–931.PubMedCrossRef
109.
Martinez-Martin, P., et al. (2011). The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Movement Disorders, 26(3), 399–406.PubMedCrossRef
110.
111.
Martinez-Martin, P., et al. (2008). SCOPA-sleep and PDSS: Two scales for assessment of sleep disorder in Parkinson’s disease. Movement Disorders, 23(12), 1681–1688.PubMedCrossRef
112.
Martín-García, S., et al. (2013). Comorbidity, health status, and quality of life in institutionalized older people with and without dementia. International Psychogeriatrics, 25(7), 1077–1084.PubMedCrossRef
113.
Nan, L., et al. (2010). Responsiveness of the EQ-5D and 8-item Parkinson’s disease questionnaire (PDQ-8) in a 4-year follow-up study. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 19(4), 565–9.CrossRef
114.
Paulo, B., et al. (2019). Motor and non-motor function predictors of mortality in Parkinson’s disease. Journal of Neural Transmission, 126(11), 1409–1415.CrossRef
115.
Raphael, S., et al. (2020). Parkinson’s disease multimodal complex treatment improves motor symptoms, depression and quality of life. Journal of Neurology, 267(4), 954–965.CrossRef
116.
Reuther, M., et al. (2007). Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism & Related Disorders, 13(2), 108–114.CrossRef
117.
Rodriguez-Blazquez, C., et al. (2010). Independent validation of the scales for outcomes in Parkinson’s disease-autonomic (SCOPA-AUT). European Journal of Neurology, 17(2), 194–201.PubMedCrossRef
118.
Rodriguez-Blazquez, C., et al. (2013). The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson’s disease. Parkinsonism & Related Disorders, 19(10), 889–893.CrossRef
119.
Seamus, K., et al. (2015). Mapping from the Parkinson’s disease questionnaire PDQ-39 to the generic EuroQol EQ-5D-3L: The value of mixture models. Medical Decision Making: An International Journal of the Society for Medical Decision Making, 35(7), 902–11.CrossRef
120.
Schrag, A., Jahanshahi, M., & Quinn, N. (2000). How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Movement Disorders, 15(6), 1112–1118.PubMedCrossRef
121.
Schröder, S., et al. (2012). Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson’s disease. International Journal of Clinical Pharmacy, 34(5), 746–756.PubMedCrossRef
122.
Taylor, P. N., et al. (2021). The effectiveness of peroneal nerve functional electrical simulation for the reduction of bradykinesia in Parkinson’s disease: A feasibility study for a randomised control trial. Clinical Rehabilitation, 35(4), 546–557.PubMedCrossRef
123.
124.
Yang, H.-J., et al. (2014). Comparison of sleep and other non-motor symptoms between SWEDDs patients and de novo Parkinson’s disease patients. Parkinsonism & Related Disorders, 20(12), 1419–1422.CrossRef
125.
Xiao, R., et al. (2016). Quality of life outcomes following cervical decompression for coexisting Parkinson’s disease and cervical spondylotic myelopathy. Spine Journal, 16(11), 1358–1366.CrossRef
126.
Deli, G., et al. (2015). Earlier and more efficiently: The role of deep brain stimulation for Parkinson’s disease preserving the working capabilities. Korábban és hatékonyabban: A mély agyi stimuláció szerepe a munkaképesség megorzésében, 68(11), 384–390.
127.
Junaid Farrukh, M., et al. (2021). Medication adherence status among patients with neurological conditions and its association with quality of life. Saudi Pharmaceutical Journal, 29(5), 427–433.PubMedPubMedCentralCrossRef
128.
Zrubka, Z., et al. (2019). A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. European Journal of Health Economics, 20, 119–132.CrossRef
129.
130.
Xin, Y., et al. (2020). Cost-effectiveness of the PDSAFE personalised physiotherapy intervention for fall prevention in Parkinson’s: An economic evaluation alongside a randomised controlled trial. BMC Neurology, 20(1), 295.PubMedPubMedCentralCrossRef
131.
Zhu, X. L., Chan, D. T., Lau, C. K., Poon, W. S., Mok, V. C., Chan, A. Y., & Yeung, C. (2014). Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: A prospective study. World neurosurgery, 82(6), 987–993.PubMedCrossRef
132.
Norlin, J. M., Kellerborg, K., & Odin, P. (2021). Patient utilities in health states based on Hoehn and Yahr and off-time in Parkinson’s disease: A Swedish register-based study in 1823 observations. PharmacoEconomics, 39(10), 1141–1149.PubMedCrossRef
133.
Noyes, K., Dick, A. W., & Holloway, R. G. (2006). Pramipexole versus levodopa in patients with early Parkinson’s disease: Effect on generic and disease-specific quality of life. Value in Health, 9(1), 28–38.PubMedCrossRef
134.
Shearer, J., et al. (2012). The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson’s disease. Journal of Neurology, 259(3), 462–468.PubMedCrossRef
135.
Shiroiwa, T., Noto, S., & Fukuda, T. (2021). Japanese population norms of EQ-5D-5L and health utilities index mark 3: Disutility catalog by disease and symptom in community settings. Value Health, 24(8), 1193–1202.PubMedCrossRef
136.
Soeteman, D. I., et al. (2005). Assessment of the burden of disease among inpatients in specialized units that provide psychotherapy. Psychiatric Services, 56(9), 1153–1155.PubMedCrossRef
137.
Soh, S.-E., et al. (2016). Health-related quality of life in people with Parkinson’s disease receiving comprehensive care. Australian Health Review, 40(6), 613–618.PubMedCrossRef
138.
Saarni, S. I., et al. (2006). The impact of 29 chronic conditions on health-related quality of life: A general population survey in Finland using 15D and EQ-5D. Quality of Life Research, 15(8), 1403–1414.PubMedCrossRef
139.
Schrag, A., et al. (2000). The EQ-5D—A generic quality of life measure—Is a useful instrument to measure quality of life in patients with Parkinson’s disease. Journal of Neurology Neurosurgery and Psychiatry, 69(1), 67–73.PubMedPubMedCentralCrossRef
140.
Schrag, A., et al. (2009). Comparative responsiveness of Parkinson’s disease scales to change over time. Movement Disorders, 24(6), 813–818.PubMedCrossRef
141.
Wade, D. T., et al. (2003). Multidisciplinary rehabilitation for people with Parkinson’s disease: A randomised controlled study. Journal of Neurology, Neurosurgery and Psychiatry, 74(2), 158–162.PubMedPubMedCentralCrossRef
142.
Tollár, J., et al. (2018). A high-intensity multicomponent agility intervention improves Parkinson patients’ clinical and motor symptoms. Archives of Physical Medicine and Rehabilitation, 99(12), 2478-2484.e1.PubMedCrossRef
143.
Stathis, P., & Papadopoulos, G. (2022). Evaluation and validation of a patient-reported quality-of-life questionnaire for Parkinson’s disease. Journal of Patient-Reported Outcomes, 6(1), 17.PubMedPubMedCentralCrossRef
144.
Martinez-Martin, P., Arroyo, S., Rojo-Abuin, J. M., Rodriguez-Blazquez, C., Frades, B., & de Pedro Cuesta, J. (2008). Burden, perceived health status, and mood among caregivers of Parkinson’s disease patients. Movement Disorders: Official Journal of the Movement Disorder Society, 23(12), 1673–1680.PubMedCrossRef
145.
Martínez-Martín, P., Rodríguez-Blázquez, C., Forjaz, M. J., Alvarez-Sánchez, M., Arakaki, T., Bergareche-Yarza, A., & Goetz, C. G. (2014). Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson’s disease patients. European Journal of Neurology, 21(3), 519–524.PubMedCrossRef
146.
Martinez-Martin, P., Rodriguez-Blazquez, C., Abe, K., Bhattacharyya, K. B., Bloem, B. R., Carod-Artal, F. J., & Chaudhuri, K. R. (2009). International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology, 73(19), 1584–1591.PubMedCrossRef
147.
von Below, D., Wallerstedt, S. M., & Bergquist, F. (2023). Validation of the Swedish patient-reported outcomes in Parkinson’s disease scale in outpatients. Movement Disorders, 38(9), 1668–1678.CrossRef
148.
Lacy, B., Piotrowski, H. J., Dewey, R. B., Jr., & Husain, M. M. (2023). Severity of depressive and motor symptoms impacts quality of life in Parkinson’s disease patients at an academic movement clinic: A cross-sectional study. Clinical Parkinsonism & Related Disorders, 8, 100180.CrossRef
149.
Steinle, A. M., Nian, H., Pennings, J. S., Bydon, M., Asher, A., Archer, K. R., & Abtahi, A. M. (2022). Complications, readmissions, revisions, and patient-reported outcomes in patients with Parkinson disease undergoing elective spine surgery: A propensity-matched analysis. Spine, 47(20), 1452–1462.PubMedCrossRef
150.
Shiroiwa, T., et al. (2016). Comparison of value set based on DCE and/or TTO data: Scoring for EQ-5D-5L health states in Japan. Value in Health, 19(5), 648–654.PubMedCrossRef
151.
152.
153.
154.
Zhao, Y. J., et al. (2010). Progression of Parkinson’s disease as evaluated by Hoehn and Yahr stage transition times. Movement Disorders, 25(6), 710–716.PubMedCrossRef
155.
Opara, J. A., Brola, W., Leonardi, M., & Błaszczyk, B. (2012). Quality of life in Parkinson’s disease. Journal of Medicine and Life, 5(4), 375–81.PubMedPubMedCentral
156.
Metagegevens
Titel
Health-related quality of life in Parkinson’s disease: systematic review and meta-analysis of EuroQol (EQ-5D) utility scores
Auteurs
Raghu Bhanupriya
Madhumitha Haridoss
Goda Suchitra Lakshmi
Bhavani Shankara Bagepally
Publicatiedatum
06-04-2024
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 7/2024
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-024-03646-8

Andere artikelen Uitgave 7/2024

What facets of physical function are most important to adults diagnosed with cancer?

Impact of caregiving on mental, self-rated, and physical health: evidence from the China health and retirement longitudinal study

Health-related quality of life measures provide information on the contributors, components, and consequences of frailty in HIV: a systematic mapping review

  • Review

Facets of physical function assessed by patient-reported outcome measures in oncology research

Quality of life in a high-risk group of elderly primary care patients: characteristics and potential for improvement

  • Open Access

Health-related quality of life in reproductive-age women on antiretroviral therapy: a cross sectional study in Ethiopia